News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,674 Results
Type
Article (40899)
Company Profile (308)
Press Release (680460)
Multimedia
Podcasts (72)
Webinars (17)
Section
Business (206887)
Career Advice (2030)
Deals (35809)
Drug Delivery (101)
Drug Development (82328)
Employer Resources (175)
FDA (16366)
Job Trends (15060)
News (349844)
Policy (32894)
Tag
Academia (2566)
Accelerated approval (15)
Adcomms (24)
Allergies (118)
Alliances (50228)
ALS (136)
Alzheimer's disease (1566)
Antibody-drug conjugate (ADC) (228)
Approvals (16478)
Artificial intelligence (407)
Autoimmune disease (88)
Automation (30)
Bankruptcy (361)
Best Places to Work (11739)
BIOSECURE Act (20)
Biosimilars (153)
Biotechnology (206)
Bladder cancer (133)
Brain cancer (46)
Breast cancer (498)
Cancer (3896)
Cardiovascular disease (325)
Career advice (1709)
Career pathing (33)
CAR-T (230)
CDC (42)
Cell therapy (616)
Cervical cancer (31)
Clinical research (69165)
Collaboration (1335)
Company closure (4)
Compensation (942)
Complete response letters (44)
COVID-19 (2691)
CRISPR (74)
C-suite (580)
Cystic fibrosis (131)
Data (4802)
Decentralized trials (2)
Denatured (23)
Depression (96)
Diabetes (427)
Diagnostics (6556)
Digital health (34)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (189)
Drug pricing (157)
Drug shortages (28)
Duchenne muscular dystrophy (195)
Earnings (89983)
Editorial (47)
Employer branding (22)
Employer resources (153)
Events (117784)
Executive appointments (940)
FDA (18847)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (15)
Funding (1203)
Gene editing (161)
Generative AI (31)
Gene therapy (487)
GLP-1 (888)
Government (4620)
Grass and pollen (7)
Guidances (370)
Healthcare (18908)
HIV (43)
Huntington's disease (36)
IgA nephropathy (62)
Immunology and inflammation (211)
Immuno-oncology (17)
Indications (59)
Infectious disease (2914)
Inflammatory bowel disease (174)
Inflation Reduction Act (13)
Influenza (92)
Intellectual property (191)
Interviews (319)
IPO (16799)
IRA (48)
Job creations (3686)
Job search strategy (1436)
Kidney cancer (15)
Labor market (73)
Layoffs (538)
Leadership (28)
Legal (7966)
Liver cancer (85)
Longevity (12)
Lung cancer (552)
Lymphoma (278)
Machine learning (30)
Management (59)
Manufacturing (601)
MASH (136)
Medical device (13645)
Medtech (13670)
Mergers & acquisitions (19901)
Metabolic disorders (1050)
Multiple sclerosis (136)
NASH (16)
Neurodegenerative disease (202)
Neuropsychiatric disorders (49)
Neuroscience (2540)
NextGen: Class of 2025 (6542)
Non-profit (4509)
Now hiring (59)
Obesity (490)
Opinion (239)
Ovarian cancer (137)
Pain (154)
Pancreatic cancer (170)
Parkinson's disease (228)
Partnered (29)
Patents (407)
Patient recruitment (326)
Peanut (52)
People (58974)
Pharmaceutical (74)
Pharmacy benefit managers (25)
Phase I (21564)
Phase II (30478)
Phase III (22619)
Pipeline (2791)
Policy (248)
Postmarket research (2570)
Preclinical (9201)
Press Release (64)
Prostate cancer (191)
Psychedelics (42)
Radiopharmaceuticals (264)
Rare diseases (617)
Real estate (6025)
Recruiting (70)
Regulatory (23698)
Reports (51)
Research institute (2366)
Resumes & cover letters (351)
Rett syndrome (15)
RNA editing (11)
RSV (67)
Schizophrenia (128)
Series A (194)
Series B (149)
Service/supplier (11)
Sickle cell disease (76)
Special edition (20)
Spinal muscular atrophy (149)
Sponsored (36)
Startups (3645)
State (2)
Stomach cancer (14)
Supply chain (94)
Tariffs (79)
The Weekly (47)
Vaccines (916)
Venture capital (65)
Weight loss (317)
Women's health (56)
Worklife (17)
Date
Today (217)
Last 7 days (900)
Last 30 days (2917)
Last 365 days (30903)
2025 (25940)
2024 (35563)
2023 (40474)
2022 (51635)
2021 (56246)
2020 (54471)
2019 (46900)
2018 (35316)
2017 (32506)
2016 (31947)
2015 (38017)
2014 (31844)
2013 (26766)
2012 (28941)
2011 (29608)
2010 (27666)
Location
Africa (740)
Alabama (77)
Alaska (7)
Arizona (274)
Arkansas (14)
Asia (39675)
Australia (6440)
California (9494)
Canada (2872)
China (895)
Colorado (398)
Connecticut (405)
Delaware (268)
Europe (86206)
Florida (1423)
Georgia (305)
Hawaii (2)
Idaho (60)
Illinois (723)
India (48)
Indiana (456)
Iowa (18)
Japan (327)
Kansas (120)
Kentucky (34)
Louisiana (18)
Maine (69)
Maryland (1239)
Massachusetts (6961)
Michigan (285)
Minnesota (549)
Mississippi (4)
Missouri (111)
Montana (29)
Nebraska (25)
Nevada (104)
New Hampshire (72)
New Jersey (2610)
New Mexico (29)
New York (2568)
North Carolina (1321)
North Dakota (8)
Northern California (4451)
Ohio (286)
Oklahoma (20)
Oregon (38)
Pennsylvania (1978)
Puerto Rico (20)
Rhode Island (43)
South America (1112)
South Carolina (49)
South Dakota (1)
Southern California (3643)
Tennessee (149)
Texas (1461)
United States (34411)
Utah (282)
Virginia (227)
Washington D.C. (77)
Washington State (792)
West Virginia (4)
Wisconsin (81)
Wyoming (2)
721,674 Results for "clover biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
June 11, 2025
·
6 min read
Press Releases
Clover Health to Report First Quarter 2025 Financial Results on May 6, 2025
April 8, 2025
·
1 min read
Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults
Clover Biopharmaceuticals, Ltd. announced positive preliminary immunogenicity and safety data in the older adult & elderly cohort from its Phase Ⅰ trial evaluating SCB-1019 – the company’s bivalent RSV prefusion-stabilized F -Trimer subunit vaccine candidate – which is based on Clover’s Trimer-Tag vaccine technology platform.
June 18, 2024
·
5 min read
Drug Development
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
Clover Biopharmaceuticals, Ltd. announced positive preliminary immunogenicity and safety data in the initial young adult cohort from its Phase I trial evaluating SCB-1019 – the company’s bivalent RSV prefusion-stabilized F -Trimer subunit vaccine candidate – which is based on Clover’s Trimer-Tag vaccine technology platform.
April 8, 2024
·
5 min read
Press Releases
Clover Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
February 18, 2025
·
1 min read
Business
Clover Health to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report fourth quarter and full year 2023 financial results after market close on Tuesday, March 12, 2024.
February 26, 2024
·
1 min read
Drug Development
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate
Clover Biopharmaceuticals, Ltd. today announced that enrollment of the first participants has been completed in a Phase Ⅰ first-in-human study evaluating the company’s RSV PreF-Trimer subunit vaccine candidate (SCB-1019), which is based on Clover’s Trimer-Tag vaccine technology platform.
December 12, 2023
·
3 min read
Clover Completes BLA Submission for Seasonal Influenza Vaccine in Brazil
Clover Biopharmaceuticals, Ltd. announced the company completes the Biologic License Application submission for its seasonal influenza vaccine to Brazilian Health Regulatory Agency.
November 6, 2023
·
3 min read
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197) today announced the launch of AdimFlu-S (QIS) in mainland China, where it is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older.
September 11, 2023
·
4 min read
Press Releases
Clover Health to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
·
1 min read
1 of 72,168
Next
